The outcome of Intracoronary Tirofiban administration at Primary Percutaneous Coronary Intervention in St-Elevation Myocardial Infarction Patients


  • Muhammad Asim Saddique Niazi Medical Complex/ Tayyab Hospital, Sargodha- Pakistan
  • Muhammad Munawar Jamshaid Niazi Medical Complex/ Tayyab Hospital, Sargodha- Pakistan
  • Shahid Abbas Department of Cardiology, Faisalabad Institute of Cardiology, Faisalabad- Pakistan
  • Komal Jabeen Institute of Physiology, University of Agricultural, Faisalabad- Pakistan


STEMI, Primary coronary intervention, Tirofiban


Background: ST-elevation myocardial infarction results from obstruction of coronary flow due to intracoronary thrombus formation. Primary PCI is the gold standard and class-I indication for revascularization following STEMI. Investigators in this study aimed to evaluate the TIMI flow and myocardial blush grade after intracoronary Tirofiban administration in patients with STEMI during the primary percutaneous coronary intervention (PPCI) and its outcome.

Methodology: This Cohort study was conducted at Cardiology Department, Niazi Medical & Dental College, Sargodha, after getting informed consent from patients with STEMI. Primary PCI was done in these patients, and two groups were formed. Tirofiban and Non-tirofiban group on basis of Tirofiban administration. Variables included TIMI Grade flow, myocardial blush, major bleeding, minor bleeding, hematoma, MACE, and mortality. P<0.05 was considered statistically significant.

Results: The mean age of the study groups was 41.64 ± 12.30 years, with 74% (N=250) males. It was seen that 39 (31.2%) vs 41 (32.8%) with p-value of 0.786 were hypertensive, 28 (22.4%) vs 34 (27.2%) diabetic were having p-value of 0.380 whereas 34 (27.2%) vs 37 (29.6%) with p-value of 0.674 were smokers. TIMI flow grades in both groups were not similar and showed significant differences, indicating that both groups were independent, with a p-value <0.05. The myocardial blush grade was compared in the two groups and the results showed that the score in both the groups was not similar, having significant differences as the p-value was 0.001; major bleeding compared with minor showed statistical insignificance, which indicated that there is a relationship between the two groups. (p-value=0.625 & 0.705 respectively).

Conclusion Administration of intracoronary Tirofiban was associated with superior clinical prognosis in terms of TIMI flow and myocardial blush grades compared with the other group at primary PCI.


Allana S, Moser DK, Ali TS, Khan AH. Sex differences in symptoms experienced, knowledge about symptoms, symptom attribution, and perceived urgency for treatment seeking among acute coronary syndrome patients in Karachi Pakistan. Heart & Lung. 2018;47(6):584-90.

Yusuf S, Wood D, Ralston J, Reddy KS. The World Heart Federation's vision for worldwide cardiovascular disease prevention. The Lancet. 2015;386(9991):399-402.

Savonitto S, De Luca G, Goldstein P, van t’Hof A, Zeymer U, Morici N, Thiele H, Montalescot G, Bolognese L. Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction.Eur. Heart J. Acute Cardiovasc Care. 2017;6(2):173-190.

Zipes DP. Braunwald's heart disease: a textbook of cardiovascular medicine. BMH Medical Journal-ISSN 2348–392X. 2018;5(2):63.




How to Cite

Saddique, M. A. ., Jamshaid, M. M. ., Abbas, S. ., & Jabeen, K. . (2022). The outcome of Intracoronary Tirofiban administration at Primary Percutaneous Coronary Intervention in St-Elevation Myocardial Infarction Patients. Pakistan Journal of Cardiovascular Interventions, 2(1), 20–27. Retrieved from